These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

276 related articles for article (PubMed ID: 9265910)

  • 1. Efficacy of olanzapine: an overview of pivotal clinical trials.
    Beasley CM; Tollefson GD; Tran PV
    J Clin Psychiatry; 1997; 58 Suppl 10():7-12. PubMed ID: 9265910
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Olanzapine: an updated review of its use in the management of schizophrenia.
    Bhana N; Foster RH; Olney R; Plosker GL
    Drugs; 2001; 61(1):111-61. PubMed ID: 11217867
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Olanzapine versus haloperidol in the treatment of schizophrenia and schizoaffective and schizophreniform disorders: results of an international collaborative trial.
    Tollefson GD; Beasley CM; Tran PV; Street JS; Krueger JA; Tamura RN; Graffeo KA; Thieme ME
    Am J Psychiatry; 1997 Apr; 154(4):457-65. PubMed ID: 9090331
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Safety of olanzapine.
    Beasley CM; Tollefson GD; Tran PV
    J Clin Psychiatry; 1997; 58 Suppl 10():13-7. PubMed ID: 9265911
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Effective resolution with olanzapine of acute presentation of behavioral agitation and positive psychotic symptoms in schizophrenia.
    Kinon BJ; Roychowdhury SM; Milton DR; Hill AL
    J Clin Psychiatry; 2001; 62 Suppl 2():17-21. PubMed ID: 11232746
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Double-blind, placebo-controlled comparison of intramuscular olanzapine and intramuscular haloperidol in the treatment of acute agitation in schizophrenia.
    Wright P; Birkett M; David SR; Meehan K; Ferchland I; Alaka KJ; Saunders JC; Krueger J; Bradley P; San L; Bernardo M; Reinstein M; Breier A
    Am J Psychiatry; 2001 Jul; 158(7):1149-51. PubMed ID: 11431240
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Clozapine, olanzapine, risperidone, and haloperidol in the treatment of patients with chronic schizophrenia and schizoaffective disorder.
    Volavka J; Czobor P; Sheitman B; Lindenmayer JP; Citrome L; McEvoy JP; Cooper TB; Chakos M; Lieberman JA
    Am J Psychiatry; 2002 Feb; 159(2):255-62. PubMed ID: 11823268
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Negative symptoms: a path analytic approach to a double-blind, placebo- and haloperidol-controlled clinical trial with olanzapine.
    Tollefson GD; Sanger TM
    Am J Psychiatry; 1997 Apr; 154(4):466-74. PubMed ID: 9090332
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A double-blind, placebo-controlled dose-response comparison of intramuscular olanzapine and haloperidol in the treatment of acute agitation in schizophrenia.
    Breier A; Meehan K; Birkett M; David S; Ferchland I; Sutton V; Taylor CC; Palmer R; Dossenbach M; Kiesler G; Brook S; Wright P
    Arch Gen Psychiatry; 2002 May; 59(5):441-8. PubMed ID: 11982448
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Superior efficacy of olanzapine over haloperidol: analysis of patients with schizophrenia from a multicenter international trial.
    Gomez JC; Crawford AM
    J Clin Psychiatry; 2001; 62 Suppl 2():6-11. PubMed ID: 11232753
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Olanzapine for primary negative symptoms.
    Licht RW
    Am J Psychiatry; 1998 Aug; 155(8):1133-4. PubMed ID: 9699711
    [No Abstract]   [Full Text] [Related]  

  • 12. Olanzapine versus placebo and haloperidol: quality of life and efficacy results of the North American double-blind trial.
    Hamilton SH; Revicki DA; Genduso LA; Beasley CM
    Neuropsychopharmacology; 1998 Jan; 18(1):41-9. PubMed ID: 9408917
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Subjective experience and D2 receptor occupancy in patients with recent-onset schizophrenia treated with low-dose olanzapine or haloperidol: a randomized, double-blind study.
    de Haan L; van Bruggen M; Lavalaye J; Booij J; Dingemans PM; Linszen D
    Am J Psychiatry; 2003 Feb; 160(2):303-9. PubMed ID: 12562577
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Depressive signs and symptoms in schizophrenia: a prospective blinded trial of olanzapine and haloperidol.
    Tollefson GD; Sanger TM; Lu Y; Thieme ME
    Arch Gen Psychiatry; 1998 Mar; 55(3):250-8. PubMed ID: 9510219
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Clinical efficacy of olanzapine].
    Yui K
    Nihon Shinkei Seishin Yakurigaku Zasshi; 1999 Jul; 19(3):101-10. PubMed ID: 10495984
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Dosing the antipsychotic medication olanzapine.
    Nemeroff CB
    J Clin Psychiatry; 1997; 58 Suppl 10():45-9. PubMed ID: 9265916
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A double-blind, controlled comparison of the novel antipsychotic olanzapine versus haloperidol or placebo on anxious and depressive symptoms accompanying schizophrenia.
    Tollefson GD; Sanger TM; Beasley CM; Tran PV
    Biol Psychiatry; 1998 Jun; 43(11):803-10. PubMed ID: 9611669
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Olanzapine versus haloperidol treatment in first-episode psychosis.
    Sanger TM; Lieberman JA; Tohen M; Grundy S; Beasley C; Tollefson GD
    Am J Psychiatry; 1999 Jan; 156(1):79-87. PubMed ID: 9892301
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Prolactin responses to acute clomipramine and haloperidol of male schizophrenic patients in a drug-free state and after treatment with clozapine or with olanzapine.
    Markianos M; Hatzimanolis J; Lykouras L; Christodoulou GN
    Schizophr Res; 2002 Jul; 56(1-2):11-7. PubMed ID: 12084414
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The efficacy of a rapid-acting intramuscular formulation of olanzapine for positive symptoms.
    Jones B; Taylor CC; Meehan K
    J Clin Psychiatry; 2001; 62 Suppl 2():22-4. PubMed ID: 11232747
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.